Ziritaxestat Phase II Success Gives Galapagos Something To Cheer
Silver Lining After Filgotinib Woes
It has been a tough couple of months for the Belgian biotech since the FDA surprisingly rebuffed its JAK inhibitor filgotinib but promising data on the oral autotaxin inhibitor ziritaxestat helped soften the blow and drive up Galapagos stock.
You may also be interested in...
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
The company explained that background immunosuppressant therapy performed better than anticipated based on scientific literature and physicians’ expectations.
Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."